Key Highlights
- Pharmaceutical giant Eli Lilly has struck a deal to acquire Centessa Pharmaceuticals at $38 per share, representing approximately $6.3 billion in value
- An additional contingent value right (CVR) worth about $9 per share could elevate the transaction value to roughly $7.8 billion
- Shares of Centessa’s U.S.-traded stock skyrocketed 46% during premarket hours following the announcement
- The deal centers on Centessa’s portfolio of sleep-wake disorder therapies
- In a concurrent move, Lilly revealed a $2.75 billion partnership with Insilico Medicine focused on AI-driven drug development
On Tuesday, Eli Lilly revealed plans to purchase Centessa Pharmaceuticals through a transaction estimated at $6.3 billion. The pharmaceutical giant is offering $38 in cash for each share of the Frankfurt-traded biotech company.
Additionally, Lilly is providing shareholders with a non-transferrable contingent value right valued at approximately $9 per share. Should this CVR be triggered, the acquisition’s overall worth could climb to around $7.8 billion.
Shares of Centessa traded in the United States soared 46% during premarket hours after the deal was made public. This substantial increase highlights the significant premium Lilly is willing to pay for access to Centessa’s sleep treatment candidates.
Centessa Pharmaceuticals plc, CNTA
The acquisition centers on treatments for sleep-wake disorders, representing a new therapeutic area for Lilly. Centessa’s specialized development programs align with what Lilly believes can achieve commercial success.
This transaction represents Lilly’s second significant announcement within two consecutive days. Just one day prior, the pharmaceutical company unveiled a $2.75 billion collaboration with Insilico Medicine aimed at commercializing AI-generated therapeutics worldwide.
The Insilico partnership, which leverages artificial intelligence for drug candidate identification, demonstrates Lilly’s strategy of combining conventional pharmaceutical research with cutting-edge technology platforms.
Expansion Into Sleep Disorder Therapeutics
The purchase of Centessa represents a deliberate strategic expansion into sleep-wake disorder medications. This therapeutic segment has garnered increasing interest among leading pharmaceutical manufacturers in recent times.
Centessa has been advancing orexin receptor agonists, a drug category that activates the brain’s wakefulness pathways. These compounds show promise for addressing conditions such as narcolepsy and persistent daytime drowsiness.
Lilly’s decision to offer a substantial premium indicates strong conviction in the clinical promise of these programs. The CVR component ensures that a portion of the total consideration depends on achieving specific future development objectives.
Artificial Intelligence Partnership Caps Active Period
The Insilico collaboration, unveiled on Monday, introduces another strategic component to Lilly’s recent corporate activity. Insilico employs artificial intelligence to engineer novel drug molecules, a methodology that could substantially reduce early discovery timelines.
Lilly indicated it will obtain licenses for and advance therapeutic candidates generated by Insilico’s technology platform. Complete financial details beyond the $2.75 billion announced figure remain undisclosed.
Revealing two transactions of this magnitude within a single 24-hour period is noteworthy even for an organization of Lilly’s stature. LLY shares traded approximately 1% higher on Tuesday morning as the market digested both announcements.
Centessa’s Frankfurt-listed shares similarly posted strong gains following the news, as the cash proposal significantly exceeded its recent market valuation.
